GENE-THERAPY UTILIZING DRUG-RESISTANCE GENES - A REVIEW
被引:27
作者:
BANERJEE, D
论文数: 0引用数: 0
h-index: 0
机构:
MEM SLOAN KETTERING CANC CTR, MOLEC PHARMACOL & THERAPEUT PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USAMEM SLOAN KETTERING CANC CTR, MOLEC PHARMACOL & THERAPEUT PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA
BANERJEE, D
[1
]
ZHAO, SC
论文数: 0引用数: 0
h-index: 0
机构:
MEM SLOAN KETTERING CANC CTR, MOLEC PHARMACOL & THERAPEUT PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USAMEM SLOAN KETTERING CANC CTR, MOLEC PHARMACOL & THERAPEUT PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA
ZHAO, SC
[1
]
LI, MX
论文数: 0引用数: 0
h-index: 0
机构:
MEM SLOAN KETTERING CANC CTR, MOLEC PHARMACOL & THERAPEUT PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USAMEM SLOAN KETTERING CANC CTR, MOLEC PHARMACOL & THERAPEUT PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA
LI, MX
[1
]
SCHWEITZER, BI
论文数: 0引用数: 0
h-index: 0
机构:
MEM SLOAN KETTERING CANC CTR, MOLEC PHARMACOL & THERAPEUT PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USAMEM SLOAN KETTERING CANC CTR, MOLEC PHARMACOL & THERAPEUT PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA
SCHWEITZER, BI
[1
]
MINEISHI, S
论文数: 0引用数: 0
h-index: 0
机构:
MEM SLOAN KETTERING CANC CTR, MOLEC PHARMACOL & THERAPEUT PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USAMEM SLOAN KETTERING CANC CTR, MOLEC PHARMACOL & THERAPEUT PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA
MINEISHI, S
[1
]
BERTINO, JR
论文数: 0引用数: 0
h-index: 0
机构:
MEM SLOAN KETTERING CANC CTR, MOLEC PHARMACOL & THERAPEUT PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USAMEM SLOAN KETTERING CANC CTR, MOLEC PHARMACOL & THERAPEUT PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA
BERTINO, JR
[1
]
机构:
[1] MEM SLOAN KETTERING CANC CTR, MOLEC PHARMACOL & THERAPEUT PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA
DRUG RESISTANCE GENES;
GENE TRANSFER;
CHEMOTHERAPY;
STEM CELLS;
D O I:
10.1002/stem.5530120404
中图分类号:
Q813 [细胞工程];
学科分类号:
摘要:
The generation of drug resistant bone marrow may facilitate the development of aggressive chemotherapeutic regimens that might otherwise be lethal due to marrow toxicity. With the availability of technology that permits in vitro manipulation of human marrow and peripheral blood stem cells, it is now possible to introduce genes that confer drug resistance to these hematopoietic progenitors. Animal models and in vitro work with human progenitors using drug resistance genes are reviewed.